MorphoSys AG announced that Astellas Pharma Inc. has exercised a pre-existing option to use MorphoSys's proprietary RapMAT technology for faster antibody optimization as part of the existing technology transfer agreements between the two companies. As a result, Astellas will have access to MorphoSys's RapMAT technology module alongside the existing installation of the company's proprietary antibody library HuCAL GOLD at Astellas' research site in Tsukuba, Japan.
The details can be read here.
No comments:
Post a Comment